Fierce Biotech1 min read
saveLilly signs $5.9B deal with Stipple to unlock oncology targets
Eli Lilly has struck a $5.9 billion deal to partner with Stipple Bio on oncology drug candidates that more precisely target tumor cells.
Eli Lilly has struck a $5.9 billion deal to partner with Stipple Bio on oncology drug candidates that more precisely target tumor cells.
comments(0)
5-min edit window · permanent after that